Bayer files prostate cancer drug darolutamide with EU regulators

After filings in the US and Japan, Bayer has submitted data to European regulators for its prostate cancer drug darolutamide.

This is the third filing in two weeks for darolutamide, meaning that the drug is now under review with regulators from three of the largest drug markets in the world.